SCHEMBL3367323

SCHEMBL3367323

O=S(=O)(Cc1ccc(F)c(Cl)c1)N1CCCC1c1nnc(-c2cccs2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.39
HPGD P15428 7/20 0.38
RAB9A P51151 7/20 0.37
SMN1; SMN2 Q16637 7/20 0.37
NPC1 O15118 5/20 0.37
ALDH1A1 P00352 4/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
KDM4E B2RXH2 4/20 0.37
TP53 P04637 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALOX15 P16050 2/20 0.37
HTT P42858 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 4/20 0.36
USP2 O75604 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370139 0.84 USP30 (0.43) HPGDSMN1; SMN2ALDH1A1KDM4ETP53
SCHEMBL3366618 0.79 SMN1; SMN2 (0.41) HPGDRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL3366848 0.75 ALDH1A1 (0.48) HPGDRAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3370504 0.74 CYP2C19 (0.43) MAPK1HPGDSMN1; SMN2ALDH1A1KDM4E
SCHEMBL3370219 0.73 KDM4E (0.49) HPGDSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL3367326 0.72 KDM4E (0.53) RAB9ASMN1; SMN2NPC1ALDH1A1GAA
SCHEMBL3366723 0.71 FKBP1A (0.42) RAB9ASMN1; SMN2NPC1TP53LMNA
SCHEMBL3369442 0.71 ALDH1A1 (0.44) MAPK1RAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL3368074 0.70 GRM5 (0.52) HPGDRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL3368542 0.70 GPR142 (0.48) ALDH1A1KDM4ETP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C MAPK1 2380/4885HPGD 292/4885RAB9A 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.